The online version of this article (https://doi.org/10.1007/s12094-018-02026-2) contains supplementary material, which is available to authorized users.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Germline mutations in BRCA1 and/or BRCA2 genes (gBRCA1/2m) are associated with an increased risk of breast cancer (BC) and ovarian cancer (OC). The aim of this study was to estimate the efficiency of providing germline BRCA1/2 testing to high-grade epithelial ovarian cancer (HGEOC) patients without family history of OC or BC and the subsequent testing and management of their relatives with gBRCA1/2m in Spain.
Incident HGEOC patients without family history of OC or BC who were gBRCA1/2m carriers and their relatives were simulated in a 50-year time horizon. The study compared two scenarios: BRCA1/2 testing vs no testing, using the perspective of the Spanish National Health Service. Cancer risk among gBRCA1/2m carriers was estimated based on their age and whether they had undergone risk-reducing surgeries. Direct healthcare costs and utilities of patients who developed EOC and BC were also included. A probabilistic sensitivity analysis (PSA) with 5 thousand simulations was developed considering ± 25% of the base-case value.
The BRCA1/2-testing scenario amounted to €13,437,897.43 while the no-testing scenario amounted to €12,053,291.17. It was estimated that the screening test improved the quality of life among the patients’ relatives by 43.8 quality-adjusted life years (QALYs). The incremental cost–utility ratio (ICUR) was €31,621.33/QALY in the base case. The PSA showed that 89.12% of the simulations were below the €50,000/QALY threshold.
Providing this screening test to HGEOC patients and their relatives is cost-effective and it allows one to identify a target population with high risk of cancer to provide effective prevention strategies.
Supplementary material 1 (PDF 158 kb)12094_2018_2026_MOESM1_ESM.pdf
Sociedad Española de Oncología Médica (SEOM). Las cifras del cáncer en España 2018. 2018.
Gabaldó Barrios X, Sarabia Meseguer MD, Marín Vera M, Sánchez Bermúdez AI, Macías Cerrolaza JA, Sánchez Henarejos P, et al. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical–pathological features in BRCA carriers and non-carriers. Fam Cancer. 2017;16:477–89. CrossRefPubMed
Evolución del test genético de BRCA1 y BRCA2 en pacientes con cáncer de mama u ovario a lo largo de una década. SEOM 2015. 2015. http://www.postersessiononline.es/312191188_es/congresos/15seom/aula/-P_192_15seom.pdf. Accessed 25 Oct 2017.
Instituto Nacional de Estadistica. (Spanish Statistical Office). http://www.ine.es/en/welcome.shtml. Accessed 7 Jun 2018.
Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al., editors. GeneReviews ®. Seattle: University of Washington; 2016. http://www.ncbi.nlm.nih.gov/books/NBK1247/. Accessed 22 Mar 2018.
Bennett MI, Ziegler L, Allsop M, Daniel S, Hurlow A. What determines duration of palliative care before death for patients with advanced disease? A retrospective cohort study of community and hospital palliative care provision in a large UK city. BMJ Open. 2016;6:e012576. CrossRefPubMedPubMedCentral
Ministerio de Sanidad, Servicios Sociales e Igualdad. Instituto de Información Sanitaria. Registro de altas. 2015.
Gómez-Batiste X, Porta-Sales J, Espinosa-Rojas J, Pascual-López A, Tuca A, Rodriguez J. Effectiveness of palliative care services in symptom control of patients with advanced terminal cancer: a Spanish, multicenter, prospective, quasi-experimental, pre-post study. J Pain Symptom Manag. 2010;40:652–60. CrossRef
Mediana de los costes de los Boletines Oficiales de las Comunidades Autónomas. 2017.
Bastida JL, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit. 2010;24:154–70. CrossRef
Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Ficha Técnica Arimidex 1 mg comprimidos recubiertos con película. 2014. In: AEMPS. https://cima.aemps.es/cima/dochtml/ft/61286/FT_61286.html. Accessed 19 Feb 2018.
National Institute for Clinical Excellence (NICE). Cost-effectiveness evidence review. Familial breast cancer: classification and care of women at risk of familial breast cancer and management of breast cancer and related risk in people with a family history of breast cancer. 2013.
Kind P, Hardman G, Macran S. UK population norms for EQ-5D. In: Centre for Health Economics, University of York; 1999. https://econpapers.repec.org/paper/chyrespap/172chedp.htm. Accessed 29 Aug 2018.
D’Andrea E, Marzuillo C, Pelone F, Vito CD, Villari P. Genetic testing and economic evaluations: a systematic review of the literature. Epidemiol Prev. 2015;39:45–50. PubMed
Areia M, Spaander MC, Kuipers EJ, Dinis-Ribeiro M. Endoscopic screening for gastric cancer: a cost-utility analysis for countries with an intermediate gastric cancer risk. United Eur Gastroenterol J. 2018;6:192–202. CrossRef
- Cost–utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain
Ana Beatriz Sánchez-Heras
- Springer International Publishing
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II